KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Accumulated Depreciation: 2021-2024

Historic Accumulated Depreciation for Xenon Pharmaceuticals (XENE) over the last 4 years, with Dec 2024 value amounting to $13.5 million.

  • Xenon Pharmaceuticals' Accumulated Depreciation rose 19.67% to $13.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $13.5 million, marking a year-over-year increase of 19.67%. This contributed to the annual value of $13.5 million for FY2024, which is 19.67% up from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Accumulated Depreciation stood at $13.5 million for FY2024, which was up 19.67% from $11.3 million recorded in FY2023.
  • Xenon Pharmaceuticals' Accumulated Depreciation's 5-year high stood at $13.5 million during FY2024, with a 5-year trough of $8.7 million in FY2022.
  • In the last 3 years, Xenon Pharmaceuticals' Accumulated Depreciation had a median value of $11.3 million in 2023 and averaged $11.1 million.
  • In the last 5 years, Xenon Pharmaceuticals' Accumulated Depreciation slumped by 34.79% in 2022 and then climbed by 29.25% in 2023.
  • Over the past 4 years, Xenon Pharmaceuticals' Accumulated Depreciation (Yearly) stood at $13.3 million in 2021, then plummeted by 34.79% to $8.7 million in 2022, then grew by 29.25% to $11.3 million in 2023, then climbed by 19.67% to $13.5 million in 2024.